Loading clinical trials...
Loading clinical trials...
Steady State Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Steady State 400 mg of Viramune® (200 mg BID), in HIV-1 Infected Subjects, an Open Label, Non Randomised, Multidose and Multistage Parallel Group Study. (ERVIR)
Conditions
Interventions
NVP XR 400 mg (KCR 25%)
NVP XR 400 mg (KCR 20%)
+4 more
Start Date
December 1, 2006
Primary Completion Date
May 1, 2007
Last Updated
July 18, 2014
NCT04142047
NCT06694805
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions